Monday, June 16, 2008

NNVC: HIV lead drug "markedly superior results"

NanoViricides Anti-HIV Lead Drug Candidate Demonstrated Substantial Improvement in Survival Time in Animal Model
Monday June 16, 7:00 am ET

Results Better Than Combination Therapy in Double-Blind Animal Study

WEST HAVEN, Conn.--(BUSINESS WIRE)--NanoViricides, Inc. (OTC BB: NNVC.OB), (the Company) said that its lead anti-HIV drug candidate demonstrated markedly superior survival results in the test animals when compared to those animals given the anti-HIV combo cocktail in a double-blind animal study. The three-drug combo cocktail used for comparison is one of the most frequently used triple combination therapies in humans.

Full text here.


No comments: